Alembic FDA Wednesday, April 15, 2026 0.00 Neutral

FDA Approves METHOTREXATE — Alembic Pharmaceuticals Inc.

# FDA Approves Alembic Pharmaceuticals' Generic Methotrexate Sodium Injection Alembic Pharmaceuticals Inc. has received FDA approval for its generic methotrexate sodium injection for intramuscular administration, expanding treatment options in the competitive market for this widely-used immunosuppressant and antimetabolite therapy. The approval is expected to increase price competition and improve patient access to methotrexate across oncology, rheumatology, and autoimmune disease indications.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day